Related Experiment Videos
Left Ventricular Thrombus
Peter J. Stokman1, Charn S. Nandra, Richard W. Asinger
1Cardiology Division 865A, Hennepin County Medical Center, 701 Park Avenue South, Minneapolis, MN 55415, USA. asing001@tc.umn.edu
Insights
Left ventricular thrombus (LVT) is a complication of myocardial infarction (MI) and dilated cardiomyopathy (DCM). Anticoagulation can prevent LVT embolism and stroke but carries bleeding risks, necessitating careful risk-benefit assessment.
Area of Science:
- Cardiology
- Vascular Medicine
- Thrombosis Research
Background:
- Left ventricular thrombus (LVT) is a significant complication in patients experiencing acute anterior myocardial infarction (MI) and those with dilated cardiomyopathy (DCM).
- The primary clinical concern with LVT is its propensity for embolization, leading to potentially devastating embolic events.
- While reperfusion therapy has reduced LVT incidence post-MI, stroke remains a critical complication, particularly following anterior MI, often linked to LVT embolization.
Purpose of the Study:
- To review the incidence, risks, and current management strategies for left ventricular thrombus (LVT) in acute myocardial infarction (MI) and dilated cardiomyopathy (DCM).
- To evaluate the efficacy and risks associated with anticoagulation therapy for LVT prevention and treatment.
- To discuss alternative diagnostic and therapeutic strategies for managing LVT and preventing cardioembolic stroke.
Main Methods:
- Review of existing literature on left ventricular thrombus (LVT) in acute myocardial infarction (MI) and dilated cardiomyopathy (DCM).
- Analysis of the role of therapeutic anticoagulation in reducing LVT formation and embolic events.
- Discussion of risk stratification and diagnostic approaches, including echocardiography, for LVT management.
Main Results:
- Therapeutic anticoagulation during acute MI reduces LVT incidence and may decrease cardioembolic strokes, particularly in anterior MI with apical dysfunction.
- Long-term anticoagulation is associated with reduced recurrent infarction and ischemic stroke but increases hemorrhagic risk, especially when combined with antiplatelet agents.
- Echocardiographic evaluation to guide anticoagulation in anterior MI is a potential strategy, though unproven. Anticoagulation is generally indicated if LVT is detected in MI or DCM.
Conclusions:
- Left ventricular thrombus (LVT) management requires balancing the benefits of anticoagulation against bleeding risks, particularly in acute myocardial infarction (MI) and dilated cardiomyopathy (DCM).
- While anticoagulation can prevent embolic events, its prophylactic use remains controversial due to potential harms.
- Further clinical studies are needed to establish optimal strategies, such as using echocardiography to guide targeted anticoagulation for LVT.
Abstract:
Left ventricular thrombus (LVT) is a frequent complication in patients with acute anterior myocardial infarction (MI) and in those with dilated cardiomyopathy (DCM). The clinical importance of LVT lies in its potential to embolize. The current treatment of patients with acute MI centers on reperfusion, and although controversial, the incidence of LVT complicating acute anterior MI is probably reduced when compared with historical controls. Nevertheless, stroke continues to be a clinically important complication of acute MI and is most common in patients with anterior MI, in part secondary to embolization of LVT. Therapeutic anticoagulation during acute MI reduces the incidence of LVT, and long-term anticoagulation has been associated with a reduction in recurrent infarction and ischemic stroke, but carries hemorrhagic risk. Primary treatment strategies for patients with acute MI center on reperfusion therapy followed by antiplatelet agents and pharmacologic blockade of abnormal neurohumoral mechanisms. Strategies to prevent stroke following infarction include risk stratification for development of LVT and embolism. For patients with anterior MI, particularly those with apical akinesis or dyskinesis, therapeutic anticoagulation reduces the number of LVT and cardioembolic strokes. However, the absolute number of ischemic strokes prevented with this strategy may only be marginal, given the anticoagulation risk, particularly if antiplatelet agents are used concurrently. An attractive alternative strategy is echocardiographic evaluation following anterior infarction with therapeutic anticoagulation reserved for those with demonstrable thrombus. The efficacy of this strategy, however, never has been proven in a clinical study. Primary prevention of cardioembolic stroke through therapeutic anticoagulation is controversial in patients with DCM; the greatest benefit would be expected for those with severe left ventricular dysfunction. If LVT is detected during the course of MI or DCM, therapeutic anticoagulation is usually indicated with the expectation that the majority of thrombi will resolve without clinical evidence of systemic embolism. Additional therapeutic intervention is rarely needed.